Russia Essential Drug Pricing — When FX Moves Force a Reregistration
A strong ruble in 2026 put pharmaceutical regulatory managers in front of a question they hadn’t been prepared for. For years, businesses had been building the case for the opposite scenario: how to justify raising a registered ЖНВЛП price when the ruble weakens. The rules are built so that a price increase is simply unavailable when the exchange rate moves the other way, and for some foreign-made drugs, recalculating against a strong ruble can push the registered price into a mandatory reduction.
The mechanism is set out in Government Decree No. 462 of 8 April 2025 (hereinafter, PP No. 462), with the calculation method defined by Decree No. 805 of 30 May 2025 (hereinafter, PP No. 805). Both documents repealed, effective 1 September 2025, Decree No. 865 of 2010 and Methodology No. 979 of 2015. The underlying logic hasn’t changed. The maximum ex-factory price on ЖНВЛП (Vital and Essential Drugs) remains a state-registered ceiling, and the exchange rate can only shift that ceiling within the bounds set by the formula.
Why an Ordinary Currency Clause Doesn’t Work Here
Paragraph 2 of Article 317 of the Civil Code of the Russian Federation allows parties to a transaction to state a contract price in foreign currency or conventional units, provided payment is made in rubles at an agreed rate. This clause protects a supplier’s margin when the ruble weakens and remains the standard hedging tool in ordinary commercial contracts, where the parties choose their own exchange-rate indicator and determination date.
Outside the ЖНВЛП list, this is exactly the clause most contracts between a manufacturer and a distributor rely on for imported active substances and excipients. The distributor prices the FX risk in, and the manufacturer recovers it by raising the price of the next raw-material shipment. For a drug on the ЖНВЛП list, that chain breaks at the last link. Wholesale and retail markups are calculated from the manufacturer’s maximum ex-factory price, and only a state reregistration procedure can change that price.
Unlike a free-market contract, the ceiling on a ЖНВЛП price moves only through a government formula. The manufacturer’s maximum ex-factory price is entered into the state register and becomes the upper bound for the entire supply chain, all the way to the pharmacy. Part 8, Article 61 of Federal Law No. 61-FZ of 12 April 2010, «On the Circulation of Medicines» (hereinafter, Law No. 61-FZ), prohibits selling a ЖНВЛП drug above its registered price. That price can change only through reregistration, and only on grounds the Government sets under Article 61 of Law No. 61-FZ.
A delay in reregistration doesn’t only hit the manufacturer’s margin. Wholesale and retail markups, set by the executive authorities of Russia’s constituent regions, are calculated as a percentage of the manufacturer’s actual ex-factory price, which cannot exceed the registered ceiling. Until the currency-based case is confirmed and the price revised, the distributor and the pharmacy keep working from the old base, and the whole ЖНВЛП supply chain depends on how quickly the certificate holder gets through reregistration.
Before 1 September 2025, the baseline rules and methodology were set by Decree No. 865 of 2010 and Methodology No. 979 of 2015. A similar currency-driven annual indexation mechanism had already appeared back in 2020, in the «special provisions» (особенности) approved by Decree No. 1771. PP No. 462 and PP No. 805 repealed No. 865 and No. 979, while the «special provisions» under No. 1771 were simply updated for the new digital procedures of the unified government portal and kept in force. The currency-adjustment mechanism itself, in detailed form, is now set out directly in Rules No. 462 — paragraphs 33, 34, 36 and 44.
| Parameter | Before 01.09.2025 | From 01.09.2025 |
|---|---|---|
| Baseline acts | PP No. 865 and Methodology No. 979 (repealed); the «special provisions» under No. 1771 (stood separately) | PP No. 462 and Methodology No. 805 replaced No. 865 and No. 979; the «special provisions» under No. 1771 were updated and kept in force |
| Validity period | Indefinite, amended piecemeal | PP No. 462 — until 01.09.2031 |
| Grounds for an increase on FX growth | A rule within the «special provisions» under No. 1771 | Paragraphs 34 and 36 of Rules No. 462 |
| Mandatory decrease | Existed under the earlier acts | Paragraph 44 of Rules No. 462, 25 business days to file |
How the Corridor Works for EAEU Manufacturers and for Foreign-Made Drugs
Rules No. 462 keep indexation on a tight schedule. An application for an increase can be filed no more than once a calendar year, and only before 1 October (Paragraph 33 of Rules No. 462; Part 2, Article 61 of Law No. 61-FZ). The size of any increase is always tied to the inflation forecast set by the federal budget law for the current year. For 2026, that forecast is 4.0 percent, under Federal Law No. 426-FZ of 28 November 2025, «On the Federal Budget for 2026 and the Planning Period of 2027 and 2028.» A year earlier, for applications filed in 2025, the ceiling was 6.8 percent under Federal Law No. 419-FZ of 30 November 2024 (as currently in force).
For drugs made by EAEU (Eurasian Economic Union) manufacturers, the grounds depend on the price segment (Paragraph 34 of Rules No. 462). For the segment up to 100 rubles inclusive, any increase in raw-material or overhead costs qualifies, capped at the inflation rate. For the segment from 100 to 500 rubles inclusive, there are two independent grounds: a raw-material cost increase driven by currency swings or supplier force majeure, or a rise in overhead costs — both also capped at the inflation rate. For drugs with no price cap, the ground works differently: if the weighted-average actual sales price came in below the registered price by no more than the inflation forecast, reregistration is allowed for an amount calculated under Methodology No. 805. Across all three of these grounds, the profitability margin cannot exceed 30 percent (Paragraph 39 of Rules No. 462); otherwise the requested price has to be scaled back at the filing stage.
Foreign-made drugs are held to a stricter test that requires three conditions to be met at the same time (Paragraph 48 of Methodology No. 805). The exchange rate of the manufacturing country’s currency against the ruble must have risen, since the date of registration or the last reregistration, by more than the current year’s inflation forecast (Paragraph 36 of Rules No. 462). The weighted-average actual import price for the reporting period must have stayed below the registered price, but by no more than that same inflation figure. And the new price cannot exceed the manufacturer’s minimum selling price in the reference countries, converted to rubles at the Bank of Russia rate averaged over the three months before filing. A formal rate increase above inflation doesn’t by itself guarantee a price increase until the other two conditions are also met.
The mechanism runs in reverse just as strictly, with no discretion involved. Paragraph 44 of Rules No. 462 obliges the certificate holder to file for a price decrease if the manufacturer has cut the foreign-currency price in the country of origin or in a reference country, and the ruble minimum, recalculated at the current rate, has fallen below the registered price. The filing deadline is 25 business days from the date the foreign price-cut decision takes effect (Paragraph 45 of Rules No. 462; Part 4, Article 61 of Law No. 61-FZ).
This exact combination came to a head in 2026. For a good part of the first half of the year the ruble traded stronger than the rate assumed in the budget calculations, and for drugs whose manufacturer had also cut the home-market price, the ruble minimum for some foreign ЖНВЛП products — recalculated at the strong rate — fell below the price already on the register. If the certificate holder misses the filing deadline, the antitrust regulator (FAS) can move to cancel the price approval on its own initiative. The Ministry of Health then removes the drug from the register of maximum ex-factory prices (Paragraphs 42, 43 and 50 of Rules No. 462).
The duty to cut a price isn’t limited to the reference drug alone. If a reference drug’s price is cut under subparagraph «a» of Paragraph 44 of Rules No. 462, holders of certificates for generic and biosimilar products sharing the same International Nonproprietary Name (INN) must file to cut their own price within the same 25 business days, if their registered price now exceeds the recalculated level (subparagraph «b» of Paragraph 44; Paragraph 46 of Rules No. 462). A separate ground applies when a second generic or biosimilar reaches the market: the first generic’s price cannot exceed a discount coefficient applied to the reference drug’s price once the competitor is registered (subparagraphs «v» and «g» of Paragraph 44; Paragraphs 47 and 48 of Rules No. 462).
| Manufacturer | Grounds for increase | Cap | Mandatory decrease |
|---|---|---|---|
| EAEU, segment up to 100 rubles | Higher raw-material or overhead costs (Para. 34 «a») | Capped at inflation | Weighted sales price below the ceiling (Para. 34 «g») |
| EAEU, segment 100-500 rubles | Currency-driven raw-material cost increase, supplier force majeure (Para. 34 «b»), or higher overheads (Para. 34 «v») | Capped at inflation, profitability up to 30% | Same, plus a FAS check |
| Foreign-made | FX growth above inflation, import price stayed within inflation of the ceiling, new price not above the reference-country price (Rules Para. 36, Methodology Para. 48) | All three conditions at once | Price cut abroad, recalculated minimum below the ceiling (Para. 44 «a», Para. 45) |
The mechanics are easier to follow with numbers. Say the manufacturing country’s currency rose 6 percent against the ruble since the last registration, while the current year’s inflation forecast is set at 4 percent. The first condition of Paragraph 36 of Rules No. 462 is met, because the rate increase exceeded inflation. If the weighted-average actual import price didn’t fall below 96 percent of the registered price, and the new price fits within the reference-country minimum, the applicant is entitled to raise the registered price.
The size of the increase still factors in the inflation rate as one input, and the final figure under Methodology No. 805 cannot exceed the value calculated against the reference-country minimum. The actual 6 percent rate increase doesn’t by itself set that limit. Clearing inflation only opens the right to file; the final size of the increase comes out of the methodology’s calculation, where the rate increase is just one of the inputs. Any currency gap above the calculated cap is absorbed from the company’s own margin, or folded into the price of the next raw-material shipment outside the regulated segment.
For generics and biosimilars, the arithmetic mirrors this. If the reference drug gets an increase, the generic has to hold to its discount coefficient against the reference drug’s new price (Paragraph 43 of Methodology No. 805). It doesn’t need its own currency-based grounds to move.
The economic review of every application is carried out by FAS (Paragraph 5 of Rules No. 462). The agency has 15 business days for that review, and the full registration or reregistration cycle, including the Ministry of Health’s part, runs to 26 business days (Paragraphs 17 and 19 of Rules No. 462). To claim a currency-based increase, an applicant has to attach raw-material contracts valid for at least three months after filing, plus documented proof of actual costs (subparagraphs «a» and «b» of Paragraph 37 of Rules No. 462). For foreign-made drugs the package is simpler, but it requires Russian translations of reference-country price data (subparagraphs «g» and «d» of Paragraph 37 of Rules No. 462).
What to Do
Identify the ground. Check whether the drug falls under Paragraph 34 of Rules No. 462 for EAEU manufacturers or Paragraph 36 for foreign-made products, and which specific subparagraph applies to your price segment.
Assemble the evidence in advance. A currency-based increase needs raw-material contracts valid for at least three months after filing, plus documented proof of actual costs (Paragraph 37 of Rules No. 462). For foreign-made drugs, gather reference-country price data with a Russian translation.
Track the exchange rate and the inflation forecast before 1 October. If the manufacturing country’s currency hasn’t risen against the ruble by more than the inflation figure in the current year’s budget law, there are no grounds for an increase, and the filing should wait until next year.
Watch reference prices for a mandatory decrease. If the manufacturer has adjusted its home-market or reference-country price, recalculate the ruble minimum at the current Bank of Russia rate and compare it against the registered price.
Budget 26 business days for the full cycle. Fifteen of those go to the FAS economic review (Paragraph 17 of Rules No. 462). Prepare the document package so it clears review on the first pass, without triggering an extra 7 business days for a request for more information.
The currency corridor for ЖНВЛП constrains a business from both directions at once. It doesn’t cover currency losses beyond the inflation rate. And it doesn’t let a company hold a price steady when the exchange rate moves the other way and a reference price abroad has fallen. For a regulatory manager, that means tracking the exchange rate and reference prices year-round, including the periods when the ruble is strengthening.
Regulatory basis:
1. Federal Law No. 419-FZ of 30 November 2024, «On the Federal Budget for 2025 and the Planning Period of 2026 and 2027» (as currently in force)
2. Government Decree No. 462 of 8 April 2025, «On State Regulation of Prices for Medicines Included in the List of Vital and Essential Drugs for Medical Use»
3. Government Decree No. 805 of 30 May 2025, «On Approval of the Methodology for Calculating Manufacturers’ Maximum Ex-Factory Prices for Medicines Included in the List of Vital and Essential Drugs for Medical Use»
4. Federal Law No. 61-FZ of 12 April 2010, «On the Circulation of Medicines,» Article 61
5. Article 317 of the Civil Code of the Russian Federation
6. Federal Law No. 426-FZ of 28 November 2025, «On the Federal Budget for 2026 and the Planning Period of 2027 and 2028»